Keystone Heart Closes $14M Series B Funding

Keystone Heart, a Caesarea, Israel-based medical device company, closed $14m in Series B funding.

The round was led by OrbiMed.

Keystone Heart is the developer of CE marked TriGuard™ Cerebral Protection Device, which is specifically designed to provide full coverage to all aortic arch takeoffs. By protecting all brain territories, the device is designed to minimize the risk of cerebral damage during TAVR (Transcatheter Aortic Valve Replacement) and other cardiovascular procedures.

The company intends to use the funds to conduct a European multi-center, randomized clinical trial during TAVR procedures, as well as a planned FDA IDE study. These studies will enable further assessment of the efficacy and performance of the TriGuard™ and are expected to generate additional clinical data to support its commercialization globally. Keystone Heart is planning additional studies to leverage the TriGuard™ product pipeline in TAVR and other cardiovascular indications.

The TriGuard™ Cerebral Protection Device is not yet commercially available in the USA.

FinSMEs

18/05/2014

Join the discussion